Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9
Paul Fields(Adaptive Biotechnologies (United States)), Katherine A. High(Spark Therapeutics (United States)), Valder R. Arruda(Children's Hospital of Philadelphia), Roland W. Herzog(Heidelberg University), Federico Mingozzi(Spark Therapeutics (United States)), Elina Armstrong(Children's Hospital of Philadelphia), Kirk Chu(Children's Hospital of Philadelphia), J. Nathan Hagstrom(Children's Hospital of Philadelphia)
Cited by 127
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Gene therapy comes of age
|Science|2018|1.4k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864